Wegovy and endometriosis: separating fact from assumption

The misconception: that Wegovy can treat endometriosis itself

A number of women with endometriosis have come across claims (often on social media) that GLP-1 medicines reduce pelvic inflammation or ease period pain directly. It is easy to see why the idea took hold. Early laboratory research has explored links between GLP-1 receptors and inflammatory pathways, and semaglutide does have well-documented anti-inflammatory properties in certain contexts. But none of that translates into a licensed or evidence-based treatment for endometriosis.

The current evidence base does not support using Wegovy to treat the lesions, adhesions or hormonal drivers of endometriosis. The NHS medicines page for semaglutide is clear that its licensed use is weight management (and cardiovascular risk reduction in eligible adults), not gynaecological conditions. Any clinician prescribing it with the expectation it will shrink endometrial tissue would be acting without evidence.

That said, the relationship between body weight and endometriosis is genuinely complicated, and dismissing the question entirely would also be unhelpful. The real picture is more nuanced.

Where weight does intersect with endometriosis

Adipose tissue is hormonally active. It produces oestrogen, and because endometriosis is an oestrogen-dependent condition, higher levels of circulating oestrogen can potentially fuel its progression and intensify symptoms. This is not a new observation; endocrinologists and gynaecologists have noted it for years. It does not mean that losing weight cures endometriosis (it does not), but it forms part of the rationale for why some women with both obesity and endometriosis are referred for weight management support.

For women exploring their options, our Wegovy overview sets out what the treatment involves, what clinical trials showed, and the full eligibility picture for the UK. It is worth reading alongside any conversation with your gynaecologist.

There is also the question of how weight-loss treatment interacts with the hormonal medicines many women with endometriosis take. Progestins, combined oral contraceptives and GnRH analogues all sit alongside any weight management plan, your prescriber needs the full picture of what you are taking. Questions about how Wegovy may affect your cycle are addressed on our page covering periods and Wegovy.

Side effects that can muddy the picture, and why it matters

Semaglutide's most common side effects are gastrointestinal: nausea, bloating, constipation, cramping, changes in bowel habit. For many women, those symptoms will be familiar. They overlap substantially with the way endometriosis presents on difficult days, and that overlap can make it harder to work out what is causing what.

This is not a reason to avoid Wegovy if you are otherwise suitable, but it is a reason to be particularly careful about communication with whoever is managing your care. If GI symptoms worsen significantly after starting or after a dose change, reporting them promptly matters, both to assess whether they are treatment-related and to rule out anything that warrants separate attention. The MHRA's Yellow Card scheme exists for exactly this kind of reporting.

Some women also find that their endometriosis symptoms shift meaningfully with dietary changes that naturally accompany treatment, reduced portion sizes, less high-fat food, improved eating patterns. Whether that contributes anything meaningful in individual cases is genuinely hard to say, and we would not overstate it. Worth a conversation with your care team, not a conclusion drawn from a Reddit thread at midnight.

What a clinical assessment looks like if you have endometriosis

Endometriosis does not automatically disqualify anyone from Wegovy. What it does mean is that the clinical picture is more detailed than usual, and a prescriber needs to consider it properly. At nume, your consultation is read by a GPhC-registered Independent Prescriber (a real clinician, not software) who reviews your health history in full before any prescription decision is made.

The standard UK eligibility for Wegovy requires a BMI of 30 or above, or 27 or above with at least one weight-related health condition. Whether endometriosis itself counts as a qualifying condition under the licence depends on clinical context; the prescriber's judgement matters here. You can find a plain-English rundown of the semaglutide treatment pathway, including how titration works and what to expect in the first few weeks, and our dedicated page on la dosis de Wegovy explains how the dose escalation schedule works in more detail.

If cost is part of your thinking, our Wegovy price comparison guide walks through how private treatment is typically priced in the UK, what those costs include (and what they sometimes do not), and where to look for a straightforward, no-subscription route. For women already managing a condition like endometriosis, having aftercare available seven days a week tends to matter more than a slightly lower headline price. If you are also living with a neurological condition, our guidance on MS and Wegovy covers how semaglutide interacts with that diagnosis and what prescribers look for in that context.

If you are ready to understand whether treatment is right for you, check your eligibility with our prescribers. There is no obligation, and the consultation is free.